a dual agonist for type 2 diabetes and obesity, significantly reduces the risk of CV death or worsening HF. The SUMMIT trial results presented at the AHA 2024 Scientific Sessions showed a 38% ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

This dataset include data for the estimation of obesity levels in individuals from the countries of Mexico, Peru and Colombia, based on their eating habits and physical condition. The data contains 17 ...

The Food and Drug Administration has added eggs to its updated list of healthy foods along with fish and vegetables ...

Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with ...

As we look back on these achievements, we recognize that they set the stage for future advancements. Join our movement to ...

Included were participants with hypertension 1 and 2 according to risk classification from the American Heart Association (16). 2. Obesity: Excess weight puts strain on the heart and increases the ...

A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as GLP-1-based drugs, this medication class ...

NEW YORK (Reuters) - The dire health effects associated with the ballooning waistlines of children and adolescents in the United States have prompted the American Heart Association to launch a new ...